FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014313582> ?p ?o ?g. }

• W2014313582 endingPage "23" @default.
• W2014313582 startingPage "716" @default.
• W2014313582 abstract "Integrin alphavbeta3 (vitronectin receptor) has been implicated in human malignant melanoma progression and angiogenesis as a receptor that provides survival signals. However, little is known about the therapeutic potential of antagonists of alphavbeta3. In this report, we characterize the activities of 2 antagonists of alphavbeta3 integrins: a human specific monoclonal antibody (MAb), 17E6, and a cyclic RGD peptide that blocked cell adhesion and induced detachment of previously substrate-attached cells in vitro. In vivo, alphavbeta3 antagonists behaved as anti-tumor drugs in a dose- and time-dependent manner. Moreover, different therapeutic treatments proved to be effective even in the therapy of established macroscopic tumor masses, thus supporting the use of these antagonists in clinical therapy. Using a panel of 6 human melanomas and 5 carcinomas, MAb 17E6 efficiently blocked the in vivo tumor growth of melanomas expressing alphavbeta3 as xenografts but did not affect the alphavbeta3-negative (although alphav integrin-positive) tumors. This demonstrated that alphavbeta3 is a pivotal integrin for the growth of human melanomas. Furthermore, since MAb 17E6 does not recognize murine alphavbeta3, the effect is due only to the direct anti-tumor activity and not to the well-known anti-angiogenic activity of alphav-integrin antagonists. Taken together, our results confirm the essential role of alphavbeta3 integrin in the growth of human malignant melanoma in vivo and provide strong evidence of the therapeutic potential of alphav-integrin antagonists for the treatment of such tumors." @default.
• W2014313582 created "2016-06-24" @default.
• W2014313582 creator A5010733262 @default.
• W2014313582 creator A5011214679 @default.
• W2014313582 creator A5027735621 @default.
• W2014313582 creator A5027867640 @default.
• W2014313582 creator A5060350068 @default.
• W2014313582 creator A5072413777 @default.
• W2014313582 creator A5075300600 @default.
• W2014313582 creator A5084006774 @default.
• W2014313582 date "2000-09-01" @default.
• W2014313582 modified "2023-10-11" @default.
• W2014313582 title "In vivo therapy of malignant melanoma by means of antagonists of alphav integrins." @default.
• W2014313582 cites W1577857859 @default.
• W2014313582 cites W1894658937 @default.
• W2014313582 cites W1971741567 @default.
• W2014313582 cites W1972719168 @default.
• W2014313582 cites W1979139036 @default.
• W2014313582 cites W1979146509 @default.
• W2014313582 cites W1980768771 @default.
• W2014313582 cites W1990105301 @default.
• W2014313582 cites W1991011809 @default.
• W2014313582 cites W2001753204 @default.
• W2014313582 cites W2011830425 @default.
• W2014313582 cites W2029773366 @default.
• W2014313582 cites W2030467501 @default.
• W2014313582 cites W2036697376 @default.
• W2014313582 cites W2046690431 @default.
• W2014313582 cites W2047551127 @default.
• W2014313582 cites W2055614158 @default.
• W2014313582 cites W2058418451 @default.
• W2014313582 cites W2059667376 @default.
• W2014313582 cites W2065097700 @default.
• W2014313582 cites W2069294982 @default.
• W2014313582 cites W2069324624 @default.
• W2014313582 cites W2071372738 @default.
• W2014313582 cites W2081099121 @default.
• W2014313582 cites W2081417168 @default.
• W2014313582 cites W2108398407 @default.
• W2014313582 cites W2113267611 @default.
• W2014313582 cites W2133321290 @default.
• W2014313582 cites W2202328126 @default.
• W2014313582 cites W2468465660 @default.
• W2014313582 cites W4250570549 @default.
• W2014313582 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10925366" @default.
• W2014313582 hasPublicationYear "2000" @default.
• W2014313582 type Work @default.
• W2014313582 sameAs 2014313582 @default.
• W2014313582 citedByCount "63" @default.
• W2014313582 countsByYear W20143135822012 @default.
• W2014313582 countsByYear W20143135822013 @default.
• W2014313582 countsByYear W20143135822014 @default.
• W2014313582 countsByYear W20143135822016 @default.
• W2014313582 countsByYear W20143135822017 @default.
• W2014313582 countsByYear W20143135822018 @default.
• W2014313582 countsByYear W20143135822019 @default.
• W2014313582 countsByYear W20143135822020 @default.
• W2014313582 countsByYear W20143135822021 @default.
• W2014313582 countsByYear W20143135822022 @default.
• W2014313582 countsByYear W20143135822023 @default.
• W2014313582 crossrefType "journal-article" @default.
• W2014313582 hasAuthorship W2014313582A5010733262 @default.
• W2014313582 hasAuthorship W2014313582A5011214679 @default.
• W2014313582 hasAuthorship W2014313582A5027735621 @default.
• W2014313582 hasAuthorship W2014313582A5027867640 @default.
• W2014313582 hasAuthorship W2014313582A5060350068 @default.
• W2014313582 hasAuthorship W2014313582A5072413777 @default.
• W2014313582 hasAuthorship W2014313582A5075300600 @default.
• W2014313582 hasAuthorship W2014313582A5084006774 @default.
• W2014313582 hasConcept C126322002 @default.
• W2014313582 hasConcept C150903083 @default.
• W2014313582 hasConcept C159654299 @default.
• W2014313582 hasConcept C164144092 @default.
• W2014313582 hasConcept C170493617 @default.
• W2014313582 hasConcept C195687474 @default.
• W2014313582 hasConcept C203014093 @default.
• W2014313582 hasConcept C207001950 @default.
• W2014313582 hasConcept C2777658100 @default.
• W2014313582 hasConcept C2780394083 @default.
• W2014313582 hasConcept C502942594 @default.
• W2014313582 hasConcept C542903549 @default.
• W2014313582 hasConcept C71924100 @default.
• W2014313582 hasConcept C86803240 @default.
• W2014313582 hasConceptScore W2014313582C126322002 @default.
• W2014313582 hasConceptScore W2014313582C150903083 @default.
• W2014313582 hasConceptScore W2014313582C159654299 @default.
• W2014313582 hasConceptScore W2014313582C164144092 @default.
• W2014313582 hasConceptScore W2014313582C170493617 @default.
• W2014313582 hasConceptScore W2014313582C195687474 @default.
• W2014313582 hasConceptScore W2014313582C203014093 @default.
• W2014313582 hasConceptScore W2014313582C207001950 @default.
• W2014313582 hasConceptScore W2014313582C2777658100 @default.
• W2014313582 hasConceptScore W2014313582C2780394083 @default.
• W2014313582 hasConceptScore W2014313582C502942594 @default.
• W2014313582 hasConceptScore W2014313582C542903549 @default.
• W2014313582 hasConceptScore W2014313582C71924100 @default.
• W2014313582 hasConceptScore W2014313582C86803240 @default.
• W2014313582 hasIssue "5" @default.

• next